Matricis.ai has initiated a clinical collaboration with SimonMed Imaging to pilot EndomAI, an artificial intelligence platform designed to enhance the detection of endometriosis through MRI scans. This partnership marks the first U.S. clinical trial of EndomAI, coinciding with the recent recognition by ACOG of MRI as a critical tool in the diagnostic pathway for endometriosis. The pilot leverages Matricis.ai’s extensive proprietary annotated dataset, which is pivotal for training AI models in gynecological imaging.

The significance of this collaboration lies in its potential to address the prolonged diagnostic delays associated with endometriosis, a condition that affects approximately 1 in 10 women of reproductive age and often goes undiagnosed for 7-10 years. By employing AI, EndomAI aims to standardize reporting, enhance lesion mapping for surgical planning, and provide decision support for follow-up care. The pilot will assess the impact of AI-assisted reporting on diagnostic consistency, lesion detection rates, and the confidence of radiologists in communicating findings to referring OB/GYNs, all while maintaining oversight from board-certified radiologists.

This initiative could significantly shift the paradigm in gynecological diagnostics, potentially reducing the time to diagnosis and improving treatment pathways for endometriosis patients. By integrating AI into clinical workflows, Matricis.ai and SimonMed are not only advancing the capabilities of radiologists but also paving the way for regulatory approval and broader commercial deployment of AI technologies in women’s health. This pilot represents a crucial step toward enhancing diagnostic accuracy and patient outcomes in a field that has historically faced challenges in timely and effective disease identification.

Source: globenewswire.com